Molina director receives $55K quarterly stock grant

ZORETIC RICHARD C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

ZORETIC RICHARD C reported acquisition or exercise transactions in this Form 4 filing.

Molina Healthcare director Richard C. Zoretic received an equity grant of 405 shares of common stock on April 1, 2026, held by the Richard Charles Zoretic Revocable Living Trust. The grant was made under the company’s 2025 Equity Incentive Plan as part of his director compensation.

The shares were valued using the closing price of $135.82 on April 1, 2026, equating to a quarterly equity award of $55,000 and an annual equity award target of $220,000. Following this grant, the trust holds a total of 9,152 Molina Healthcare shares.

Insider Trade Summary

Grant/Award: 405 shares

Grant/Award 1 txn

Insider ZORETIC RICHARD C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	405	$135.82	$55K

Holdings After Transaction: Common Stock — 9,152 shares (Indirect, Held by trust)

Footnotes (4)

1. F1. Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.
2. F2. The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.
3. F3. Represents the closing price of the Issuer's common stock on April 1, 2026.
4. F4. All shares held by the Richard Charles Zoretic Revocable Living Trust.

Key Figures

Shares granted: 405 shares Grant price: $135.82/share Quarterly equity award value: $55,000 +2 more

5 metrics

Shares granted 405 shares Equity grant to director on April 1, 2026

Grant price $135.82/share Closing price on April 1, 2026 used to size award

Quarterly equity award value $55,000 One quarter of annual director equity award

Annual equity award target $220,000 Aggregate annual equity award per director

Total shares held after grant 9,152 shares Held by Richard Charles Zoretic Revocable Living Trust

Key Terms

2025 Equity Incentive Plan, annual equity award, Revocable Living Trust, indirect ownership

4 terms

2025 Equity Incentive Plan financial

"Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director."

annual equity award financial

"The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted..."

Revocable Living Trust financial

"All shares held by the Richard Charles Zoretic Revocable Living Trust."

indirect ownership financial

"direct_or_indirect: "I" and nature_of_ownership: "Held by trust" indicate indirect ownership via trust."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Molina Healthcare (MOH) director Richard Zoretic report in this Form 4?

Richard C. Zoretic reported receiving 405 shares of Molina Healthcare common stock as an equity grant. The award was made under the 2025 Equity Incentive Plan and is held by his revocable living trust as part of his regular director compensation.

What was the value of the Molina Healthcare (MOH) equity grant to director Richard Zoretic?

The quarterly equity grant to Richard Zoretic was valued at $55,000, based on Molina Healthcare’s $135.82 closing share price on April 1, 2026. This quarterly amount reflects one quarter of an annual equity award target of $220,000 for each director.

How many Molina Healthcare (MOH) shares does Richard Zoretic’s trust hold after this grant?

After the April 1, 2026 grant, the Richard Charles Zoretic Revocable Living Trust holds 9,152 shares of Molina Healthcare common stock. This total includes the newly granted 405 shares received as part of Zoretic’s ongoing director equity compensation program.

Is the Molina Healthcare (MOH) Form 4 for Richard Zoretic an open-market stock purchase?

No, the transaction is not an open-market purchase. It is a grant of 405 shares under Molina Healthcare’s 2025 Equity Incentive Plan, awarded as director compensation and priced at the $135.82 closing share price on April 1, 2026 for valuation purposes.

How is Molina Healthcare (MOH) compensating directors with equity in 2026?

Each director’s annual equity compensation is set at $220,000, delivered in four quarterly grants of $55,000. The number of shares per grant, such as the 405 shares for Richard Zoretic, is based on Molina Healthcare’s closing stock price on the applicable grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZORETIC RICHARD C

(Last) (First) (Middle)

200 OCEANGATE

SUITE 100

(Street)

LONG BEACH CALIFORNIA 90802

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MOLINA HEALTHCARE, INC. [ MOH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A(1)		405(2)	A	$135.82(3)	9,152	I	Held by trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of stock under the Issuer's 2025 Equity Incentive Plan in connection with the Reporting Person's services as a Director.

2. The aggregate dollar value of the annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter, based on the closing price of the Issuer's common stock on such day. The closing price of the Issuer's common stock on April 1, 2026 was $135.82, which resulted in a grant of 405 shares.

3. Represents the closing price of the Issuer's common stock on April 1, 2026.

4. All shares held by the Richard Charles Zoretic Revocable Living Trust.

Remarks:

	Jeff D. Barlow, by power of attorney for Richard C. Zoretic	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)